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ABSTRACT
Background  Fibromyalgia is characterised by chronic 
musculoskeletal pain and multiple symptoms including 
fatigue, multidimensional function impairment, sleep 
disturbance and tenderness. Along with pain and 
fatigue, non-restorative sleep is a core symptom of 
ﬁ  bromyalgia. Sodium oxybate (SXB) is thought to reduce 
non-restorative sleep abnormalities. This study evaluated 
effects of SXB on ﬁ  bromyalgia-related pain and other 
symptoms.
Methods  573 patients with ﬁ  bromyalgia according to 
1990 American College of Rheumatology criteria were 
enrolled at 108 centres in eight countries. Subjects 
were randomly assigned to placebo, SXB 4.5 g/night or 
SXB 6 g/night. The primary efﬁ  cacy endpoint was the 
proportion of subjects with ≥30% reduction in pain visual 
analogue scale from baseline to treatment end. Other 
efﬁ  cacy assessments included function, sleep quality, 
effect of sleep on function, fatigue, tenderness, health-
related quality of life and subject’s impression of change 
in overall wellbeing.
Results  Signiﬁ  cant improvements in pain, sleep and 
other symptoms associated with ﬁ  bromyalgia were 
seen in SXB treated subjects compared with placebo. 
The proportion of subjects with ≥30% pain reduction 
was 42.0% for SXB4.5 g/night (p=0.002) and 51.4% 
for SXB6 g/night (p<0.001) versus 26.8% for placebo. 
Quality of sleep (Jenkins sleep scale) improved by 20% 
for SXB4.5 g/night (p≤0.001) and 25% for SXB6 g/night 
(p≤0.001) versus 0.5% for placebo. Adverse events 
with an incidence ≥5% and twice placebo were nausea, 
dizziness, vomiting, insomnia, anxiety, somnolence, 
fatigue, muscle spasms and peripheral oedema.
Conclusion  These results, combined with ﬁ  ndings 
from previous phase 2 and 3 studies, provide supportive 
evidence that SXB therapy affordsimportant beneﬁ  ts 
across multiple symptoms in subjects with ﬁ  bromyalgia.
Chronic musculoskeletal pain is common, and 
causes distress and reduced quality of life.1 Patients 
with chronic musculoskeletal pain frequently expe-
rience unrefreshing sleep,2 and while it seems logi-
cal to assume that pain leads to disturbed sleep, 
there is increasing evidence that dysfunctional 
sleep leads to hyperalgesia and allodynia.3–6 These 
symptoms are the prototypical features of ﬁ  bromy-
algia and formed the basis for the 1990 diagnostic 
criteria promulgated by the American College of 
Rheumatology (ACR).7 Based on these ACR criteria, 
ﬁ  bromyalgia has a population prevalence of 2–5% 
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and incurs substantial medical costs.8 9 While ﬁ  bro-
myalgia is deﬁ  ned in terms of pain,7 most patients 
are multisymptomatic, with core outcome domains 
that include pain, fatigue, multidimensional func-
tion, sleep disturbance, patient global impression of 
change (PGIC) in condition and tenderness.10
Polysomnographic studies in ﬁ  bromyalgia patients 
typically report non-refreshing sleep associated with 
abnormal polysomnographic ﬁ  ndings—in  particu-
lar, alpha intrusion and reduced slow-wave sleep 
(SWS).11 Furthermore, Moldofsky et al12 showed 
that ﬁ  bromyalgia-like symptoms could be induced 
in healthy normal volunteers by the deprivation of 
stage 4 (N3) sleep. There is also increasing evidence 
that ‘non-restorative’ sleep and its inﬂ  uence  on 
peripheral functions promotes hyperalgesia, fatigue 
and bodily hypersensitivity.5 10 Although the detailed 
mechanisms underlying sleep problems in ﬁ  bro-
myalgia are not known, given that epidemiological 
evidence suggests that the attainment of restorative 
sleep resolves chronic widespread pain,13 it is reason-
able to hypothesise that sleep disturbance is a funda-
mental component of ﬁ  bromyalgia pathophysiology, 
and the amelioration of sleep disturbance may be 
clinically beneﬁ  cial to ﬁ  bromyalgia patients.
Sodium oxybate (SXB) is the sodium salt of 
γ-hydroxybutyrate, an endogenous compound 
found in the central nervous system and a metabo-
lite of γ-aminobutyric acid. The drug is approved in 
the USA, Canada and Europe for the treatment of 
symptoms in narcolepsy.
SXB is thought to improve the quantity and qual-
ity of SWS.14 Previously, Scharf et al15 observed that 
some narcoleptic subjects with co-existing ﬁ  bromy-
algia experienced a reduction of pain and fatigue 
while being treated with SXB. They conducted a 
small placebo-controlled study using polysom-
nography and reported that SXB reduced pain and 
fatigue in subjects with ﬁ  bromyalgia and dramati-
cally reduced non-restorative sleep abnormalities 
(α intrusion and decreased SWS) associated with 
ﬁ  bromyalgia.16 More recently, a larger, phase 2, 
placebo-controlled trial reported beneﬁ  cial effects 
of two dosages of SXB (4.5 or 6 g) on multiple 
symptoms in patients with ﬁ  bromyalgia, and the 
SXB 6 g dose improved sleep physiology as mea-
sured by polysomnography.17 18 In addition, the 
ﬁ  rst large, multicentre, phase 3, placebo-controlled 
trial conducted in the USA demonstrated clinically 
important beneﬁ  ts of SXB on multiple symptoms 
in subjects with ﬁ  bromyalgia.19
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ﬁ  rst 2 weeks and then SXB 6 g/night for the remaining 12 weeks. 
All study medication was taken nightly in two equal doses, one 
at bedtime and the second 2.5–4 h later.21 Subjects discontinuing 
early were followed for an additional 2 weeks.
Study outcomes
Efﬁ  cacy
Assessments were based on recommendations of the 9th 
Working Group of Outcome Measures in Rheumatology 
Clinical Trials (OMERACT), which includes measurement of 
tenderness and questionnaires on the domains of pain, fatigue, 
multidimensional function, sleep disturbance and global impres-
sion of change.10
Primary endpoint
The primary efﬁ  cacy endpoint was the proportion of subjects 
recording 30% or greater reduction in pain VAS scores from the 
average baseline week value to the average ﬁ  nal treatment week 
(week 14) value.
Secondary endpoints
Secondary efﬁ  cacy parameters included mean change from base-
line in fatigue VAS scores; the proportion of subjects with a 30% or 
greater reduction on the ﬁ  bromyalgia impact questionnaire (FIQ) 
total score;22 sleep assessment using the Jenkins sleep scale (JSS), 
a validated measure of sleep quality;23 24 health-related quality of 
life based on the Medical Outcomes Study 36-item short-form 
health survey (SF-36);25 and the EuroQol-5 dimensions (EQ-5D) 
self-report questionnaire, comprising ﬁ  ve aspects of quality of life 
and overall health state.26 Overall impression of wellbeing was 
evaluated by subjects using the PGIC, and the impact of daytime 
sleepiness and tiredness on activities of daily living was evalu-
ated by subjects using the functional outcomes of sleep question-
naire (FOSQ).27 The proportion of subjects meeting composite 
response measures was also determined. Fibromyalgia composite 
responders were predeﬁ  ned as subjects who had 30% or greater 
reduction in pain, a PGIC response of ‘much better’ or ‘very 
much better’ and a 30% or greater reduction in FIQ total score. 
The FIQ has 10 domains: pain, fatigue, sleep, physical function, 
work, general health, participation, stiffness, anxiety and depres-
sion. Functional composite responders were deﬁ  ned as subjects 
who had 30% or greater reduction in pain, a PGIC response of 
‘much better’ or ‘very much better’, plus improved SF-36 scores 
using two cutoffs—scores of 5 or greater and scores 6 or greater. 
Clinician assessments included tenderness using the manual ten-
der point survey (MTPS),28 with a tender point count and tender 
point index and the clinician global impression of change.29
The number needed to treat (NNT) and its 95% CI were esti-
mated as a post-hoc analysis for pain reduction (30%, 50% and 
80%) and improvement in FIQ (14% and 30%).
Tolerability and safety
All observed or spontaneously reported treatment-emergent 
adverse events (AE) were determined by prespeciﬁ  ed  criteria 
and recorded. Physical ﬁ  ndings, including vital signs, were also 
recorded, and 12-lead electrocardiograms were performed (at 
screening and at the end of the treatment period). Clinical labora-
tory tests (haematology, chemistry and urinalysis) were performed 
at screening, week 4 and the end of the treatment period.
Statistical analyses
Efﬁ   cacy was assessed in the intent-to-treat population. For 
continuously distributed outcomes, the mean change in an 
  active-treatment group (SXB 4.5 g/night or SXB 6 g/night) was 
This paper reports the results of a second phase 3, randomised, 
double-blind, placebo-controlled trial that evaluated the efﬁ  cacy 
and safety of SXB in ﬁ  bromyalgia patients from the USA and 
seven European countries.
METHODS
Study design and subjects
This double-blind, placebo-controlled, parallel-group study 
examined the efﬁ  cacy and safety of SXB 4.5 g/night, SXB 6 g/
night and placebo in ﬁ  bromyalgia subjects. The study consisted 
of a screening and washout/withdrawal period, a baseline week, 
a 14-week randomised treatment and a post-treatment follow-
up. Subjects were enrolled from February 2007 to April 2009 at 
108 study centres in eight countries (France, Germany, Italy, The 
Netherlands, Poland, Spain, UK and USA). Women or men aged 
18 years or over had to meet the ACR criteria for ﬁ  bromyalgia,7 
have a body mass index less than 40 kg/m2, and have an aver-
age score of 50 or greater on a 100-mm pain visual analogue 
scale (VAS) at baseline. Subjects had to discontinue medications, 
herbal remedies and/or devices that might inﬂ  uence outcome; 
non-pharmacological treatments for ﬁ   bromyalgia needed to 
remain unchanged, and only paracetamol (acetaminophen) was 
allowed as rescue medication. Subjects with a body mass index 
of 35 kg/m2 or greater and less than 40 kg/m2 had to have poly-
somnography at screening to rule out obstructive sleep apnoea 
(OSA). Subjects with OSA had to be on stable continuous posi-
tive airway pressure (CPAP) for 30 days prior to baseline and 
continue CPAP for the study duration.
Potential subjects were excluded if they had any painful dis-
order other than ﬁ  bromyalgia and/or any medical or psychiatric 
condition that might compromise study participation (including 
current major depressive disorder and generalised anxiety disor-
der). They were also excluded if they had a current or previous 
substance-use disorder, including alcohol abuse; had previously 
taken γ-hydroxybutyrate or SXB; or had previously participated 
in clinical trials with SXB.
This study was conducted in compliance with the Declaration of 
Helsinki, International Conference on Harmonisation Guidelines 
for Good Clinical Practice, the US Code of Federal Regulations 
and Directives of the European Parliament and was approved by 
the ethics committee or institutional review board at every study 
site. All participants provided written informed consent.
Procedures
During screening, eligibility evaluations included assessment for 
sleep apnoea by clinical judgement, assisted by the Berlin ques-
tionnaire, or polysomnography to rule out OSA.20 All screened 
subjects on any prohibited medications underwent a washout 
for up to 30 days. At baseline, eligible subjects were issued elec-
tronic diaries (PHT Corporation, Charlestown, Massachusetts, 
USA) to rate their current pain and fatigue three times a day 
(morning, afternoon and evening) on a VAS ranging from 0 
(none) to 100 mm (worst imaginable) throughout the following 
week and to record rescue medication use.
Subjects who met all eligibility criteria and demonstrated 
competency using the diary were randomly assigned to receive 
an oral solution of SXB 4.5 g/night, SXB 6 g/night, or placebo 
matched to active-treatment volume. The randomisation code 
was generated using permuted blocks (block size of six) and 
implemented centrally by an interactive voice-response sys-
tem. Treatment assignment remained blinded until the study 
database was locked and ready for analysis. Subjects randomly 
assigned to SXB 6 g/night received SXB 4.5 g/night during the 
26_annrheumdis-2011-200418.indd   936 26_annrheumdis-2011-200418.indd   936 5/4/2012   5:44:24 PM 5/4/2012   5:44:24 PMClinical and epidemiological research
Ann Rheum Dis 2012;71:935–942. doi:10.1136/annrheumdis-2011-200418 937
assessments and JSS total score. In addition, a post-hoc analysis 
using Pearson’s correlation coefﬁ  cient was conducted between 
the changes in the JSS and FOSQ total scores with the changes 
in pain VAS, FIQ total score, PGIC and fatigue VAS. Finally, a 
post-hoc analysis was conducted of the proportion of subjects 
with a 14% or greater reduction in the FIQ total score, which is 
the minimal clinically important difference (MCID) in the FIQ.
All subjects who received at least one dose of study medica-
tion (SXB or placebo) were included in the safety analysis. AE, 
including serious AE, were coded using the Medical Dictionary 
for Regulatory Activities (MedDRA, version 9.1). Treatment-
emergent AE were deﬁ   ned as events with onset, worsened 
severity or increased intensity on or after the date of randomi-
sation and through the day after the last dose of study drug. 
compared with that for placebo using analysis of variance models 
adjusted for site and treatment-group-by-site interaction. If the 
p value for an interaction exceeded 0.1, the term was dropped 
from the model. For binary outcomes, a χ2 test was used to 
compare the proportion of responders (percentage of subjects 
achieving a prespeciﬁ  ed change) in an active-treatment group 
with placebo. All outcomes were assessed by last observation 
carried forward. In addition, all outcomes were assessed using 
the prespeciﬁ  ed baseline observation carried forward method. 
Statistical analysis was performed using SAS version 9.1 for 
Windows, and all testing was two-sided with a signiﬁ  cance 
level of 5%. Post-hoc correlation analyses using Pearson’s cor-
relation coefﬁ  cient were performed between the FIQ subscale 7 
(measure of restorative sleep) and pain VAS, fatigue VAS, global 
Figure 1  Subject disposition. SXB4.5g, sodium oxybate 4.5 g/night. SXB6g, sodium oxybate 6 g/night.
Table 1  Baseline demographic and clinical characteristics of the study population*
Characteristic Placebo (n=188) SXB4.5g (n=195) SXB6g (n=190) Total (N=573)
Age, years   46.8 (9.7)   46.6 (10.8)   46.4 (11.6)   46.6 (10.7)
Female, n (%) 168 (89.4) 175 (89.7) 170 (89.5) 513 (89.5)
Race, n (%)
  White 173 (92.0) 182 (93.3) 169 (88.9) 524 (91.4)
 Black  10  (5.3)  11  (5.6)  18  (9.5)  39  (6.8)
 Other   5  (2.7)   2  (1.0)   3  (1.6)  10  (1.7)
Body mass index, kg/m2  27.4  (4.7)  27.4  (4.3)  28.0  (4.8)  27.6  (4.6)
Time since ﬁ  rst ﬁ  bromyalgia symptoms, years, mean (SD)     9.3 (7.9)     9.9 (8.8)     9.9 (9.5)     9.7 (8.8)
Time since ﬁ  rst ﬁ  bromyalgia diagnosis, years, mean (SD)   5.1 (6.3)     5.1 (5.5)     4.4 (5.0)     4.9 (5.6)
Previous pharmacological treatment for ﬁ  bromyalgia, n (%) 182 (96.8) 185 (94.9) 182 (95.8) 549 (95.8)
Previous non-pharmacological treatment for ﬁ  bromyalgia, n (%) 132 (70.2) 128 (65.6) 138 (72.6) 398 (69.5)
Baseline scores
  Pain VAS (scale 0–100)   72.6 (12.9)   70.5 (13.0)   72.2 (14.0)   71.8 (13.3)
  Fatigue VAS (scale 0–100)   73.5 (15.0)   71.1 (15.4)   71.5 (17.2)   72.0 (15.9)
  TPC (scale 0–18), median (range)†   18.0 (8, 18)   18.0 (11, 18)   18.0 (12, 18)   18.0 (8, 18)
  TPI (scale 0–72)   39.5 (12.2)   37.9 (11.7)   38.2 (11.4)   38.6 (11.7)
  MTPS (scale 0–180) 111.3 (33.3) 112.3 (32.4) 109.2 (30.9) 111.0 (32.2)
  FIQ total score (scale 0–100)   63.7 (14.1)   62.3 (15.2)   62.1 (15.1)   62.7 (14.8)
  SF-36 PCS (scale 0–100)   29.1 (7.9)   29.6 (8.7)   30.8 (7.5)   29.8 (8.1)
  EQ-5D overall health state   46.6 (22.95)   48.8 (22.25)   47.4 (24.00)   47.6 (23.06)
  JSS total score (scale 0–20), median (range)†   16.0 (3, 20)   16.0 (0, 20)   16.0 (2, 20)   16.0 (0, 20)
  FOSQ (scale 5–20)   13.4 (3.8)   13.4 (3.8)   13.7 (3.8)   13.5 (3.8)
  CGIS (scale 1–7)   4.3  (1.1)   4.5  (1.0)   4.4  (1.0)   4.4  (1.0)
*Except when indicated otherwise, values are mean (±SD).
†Median values are presented due to skewed distribution of data.
CGIS, clinical global impression of severity; EQ-5D, EuroQol-5 dimensions self-report questionnaire; FIQ, ﬁ  bromyalgia impact questionnaire; FOSQ, functional outcomes of sleep 
questionnaire; JSS, Jenkins sleep scale; MTPS, manual tender point survey; PCS, physical component summary; SD, standard deviation; SF-36, Medical Outcomes Study 36-item 
short-form health survey; SXB4.5g, sodium oxybate 4.5 g/night; SXB6g, sodium oxybate 6 g/night; TPC, tender-point count; TPI, tender-point index; VAS, visual analogue scale.
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baseline were signiﬁ  cantly greater for both SXB doses versus 
placebo as early as week 1 and continued to week 14 (p<0.001 
at all time points). The proportion of responders on the ﬁ  bro-
myalgia syndrome composite score was signiﬁ  cantly greater 
for SXB 4.5 g/night (p=0.005) and SXB 6 g/night (p<0.001) ver-
sus placebo. Analysis of the functional composite score based 
on the lower cut-off for SF-36 scores (≥5) demonstrated that 
signiﬁ  cantly greater proportions of subjects treated with SXB 
4.5 g/night (p=0.004) and SXB 6 g/night (p<0.001) showed sig-
niﬁ  cant clinical improvement versus placebo. Using an SF-36 
cut-off of 6, the functional composite score showed that sig-
niﬁ  cantly greater proportions of subjects were responders with 
SXB 4.5 g/night (p=0.004) and SXB 6 g/night (p<0.001) versus 
placebo.
Signiﬁ   cantly greater increases in the SF-36 physical com-
ponent summary score were observed for SXB 4.5 g/night 
(p=0.002) and SXB 6 g/night (p=0.003) versus placebo, indicating 
a beneﬁ  cial effect of SXB on physical functioning. Numerically 
greater increases in the EQ-5D overall health state scores were 
also observed for both SXB doses versus placebo.
Sleep
A signiﬁ   cant improvement in sleep quality was observed by 
changes from baseline in JSS scores for SXB 4.5 g/night and SXB 
6 g/night versus placebo (p<0.001). Improvements in functionality 
Subjects were counted once for maximum severity of an event, 
preferred term and system organ class.
The sample size of 525 subjects was planned based on data 
from an earlier study to provide at least 90% power to detect a 
target treatment difference in the primary endpoint for one dose 
of SXB based on χ2 tests with a signiﬁ  cance level of 5%.
RESULTS
Study subjects and baseline characteristics
A total of 573 subjects was randomly assigned and 376 subjects 
(65.6%) completed the study (ﬁ  gure 1). Although early discon-
tinuations due to lack of efﬁ  cacy occurred more frequently with 
placebo compared with SXB 4.5 g/night or SXB 6 g/night, the 
differences were less marked than for early discontinuations due 
to AE, which occurred in more subjects on SXB 4.5 g/night or 
SXB 6 g/night than on placebo (ﬁ  gure 1).
Baseline characteristics were well balanced across treatment 
groups; the majority of subjects were white and female (table 1). 
The mean baseline clinical global impression of severity score of 
4.4 indicated moderately severe illness, and other baseline aver-
ages indicated clinically signiﬁ  cant pain, fatigue, sleep impair-
ment and impaired functionality.
Efﬁ  cacy
Pain
During 14 weeks of treatment, pain was reduced with both SXB 
doses relative to placebo when assessed by multiple pain param-
eters. At week 14, the proportion of subjects with 30% or greater 
reduction in pain VAS, the primary efﬁ  cacy endpoint, was signiﬁ  -
cantly greater with SXB 4.5 g/night (42%, p=0.002) and SXB 6 g/
night (51.4%, p<0.001) versus placebo (26.8%; table 2). Similarly, 
the proportion of subjects with 50% or greater reduction in pain 
VAS was signiﬁ  cantly greater with both doses of SXB versus pla-
cebo (p≤0.003), and 80% or greater reduction in pain VAS was 
signiﬁ  cantly greater with SXB 6 g/night versus placebo (p=0.003; 
table 2). Signiﬁ  cant reductions in pain VAS were observed as 
early as week 1 and persisted through week 14   (ﬁ  gure 2A), indi-
cating that pain reduction was rapid and sustained.
Categorical outcomes were analysed using the χ2 test. 
Continuous outcomes were analysed using analysis of variance 
with treatment and centre as the factors. Interaction of centre by 
treatment was included if it was signiﬁ  cant (p<0.1).
Tenderness
Signiﬁ  cant differences were observed in MTPS for SXB 4.5 g/night 
and SXB 6 g/night and in tender-point count and tender-point 
index for the SXB 4.5 g/night group only versus placebo (table 2).
Fatigue
For both SXB doses, there were signiﬁ  cant reductions in fatigue 
versus placebo (table 2). These decreases were observed as early 
as week 1 and persisted through week 14, suggesting rapid and 
sustained improvement (ﬁ  gure 2B).
Multidimensional function
Post-hoc analysis of the FIQ using the MCID of 14% or greater 
reduction in the total score30 showed that signiﬁ  cantly greater 
proportions of subjects reported clinically important differ-
ences with both SXB doses versus placebo (p<0.001; table 2). 
In a preplanned analysis, when a more stringent criterion of 
30% or greater reduction in the FIQ total score was used to 
deﬁ  ne moderate/good responders, signiﬁ  cantly greater propor-
tions of subjects in the SXB groups met the criterion versus pla-
cebo (p<0.001; table 2). Mean changes in total FIQ scores from 
Figure 2  (A) Change from baseline in mean pain VAS score over 
time (ITT population, LOCF analysis). (B) Change from baseline in mean 
fatigue VAS score over time (ITT population, LOCF analysis). Note: error 
bars=SEM. ITT, intent to treat; LOCF, last observation carried forward; 
LS, least squares; SEM, standard error of LS mean; SXB4.5g, sodium 
oxybate 4.5 g/night; SXB6g, sodium oxybate 6 g/night; VAS, visual 
analogue scale.
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Global impression of change
Signiﬁ   cantly greater proportions of subjects reported feeling 
‘much better’ or ‘very much better’ at week 14 by PGIC with 
SXB 4.5 g/night and SXB 6 g/night versus placebo (both p<0.001; 
table 2). Similarly, signiﬁ  cantly greater proportions of subjects 
in both SXB groups versus placebo (both p<0.001) had their 
condition rated as ‘very much improved’ or ‘much improved’ 
by investigators using the clinical global impression of change 
(table 2).
Number needed to treat
Table 3 shows the NNT for pain reduction and improvement in 
FIQ. The NNT represents the number of patients who would 
need to be treated with SXB for one additional patient to improve 
over the number of patients who would improve if placebo had 
been used. For all levels of pain reduction and multidimensional 
function, numerically fewer patients would need to be treated 
with SXB 6 g/night to obtain an improvement.
For all efﬁ   cacy endpoints, results consistent with the last 
observation carried forward analysis were observed with the 
baseline observation carried forward analysis (data not shown).
related to sleep, as measured by mean changes from baseline in 
FOSQ scores, were also signiﬁ  cantly greater for SXB 4.5 g/night 
(p=0.003) and SXB 6 g/night (p=0.004) versus placebo.
In post-hoc analyses, there were strong correlations between 
the FIQ subscale 7, which is a subjective measure of restorative 
sleep (‘tired upon awakening’; responses ranging from 0 indi-
cating ‘awoke well rested’ to 10 indicating ‘awoke very tired’), 
and pain VAS (r=0.68; p<0.001), fatigue VAS (r=0.78; p<0.001), 
global assessments (PGIC, r=0.59; p<0.001) and JSS total score 
(r=0.56; p<0.001). Strong correlations were also demonstrated 
between changes from baseline in pain VAS and fatigue VAS 
(r=0.84; p<0.001) and between the change in pain VAS and func-
tion (FIQ total score; r=0.78; p<0.001).
In addition, post-hoc analyses demonstrated a statistically 
signiﬁ  cant association between the changes in sleep measures 
(JSS and FOSQ) and the changes in other clinical outcomes (pain 
VAS, FIQ total score, PGIC fatigue VAS). These associations 
were of moderate strength, with the highest correlation coef-
ﬁ  cient between the sleep measures and multidimensional func-
tion (FIQ). These data are presented in a supplementary table, 
available online only.
Table 2  Changes in outcome variables from baseline to endpoint in subjects with ﬁ  bromyalgia after blinded treatment with 4.5 g or 6 g sodium 
oxybate, compared with placebo*
Placebo Sodium oxybate
Outcome (n=188) 4.5 g (n=195) p Value vs placebo 6 g (n=190) p Value vs placebo
Pain and tenderness
 Pain  VAS
   n  (%)  of  responders
      ≥30% criteria 49 (26.8) 81 (42.0) 0.002 94 (51.4) <0.001
      ≥50% criteria 28 (15.3) 54 (28.0) 0.003 69 (37.7) <0.001
      ≥80% criteria 11 (6.0) 22 (11.4) NS 29 (15.8) 0.003
Pain VAS (change in score from baseline) −11.9±2.0 −19.2±2.0 0.010 −23.4±1.9 <0.001
 Tender  point
      TPC (change in score from baseline), median (range)† 0 (−16, 5) 0 (−16, 4) 0.003 0 (−17, 4) NS
      TPI (change in score from baseline) −5.5±1.0 −9.1±1.0 0.007 −7.8±1.0 NS
      MTPS (change in score from baseline) −14.1±2.6 −27.9±2.6 <0.001 −21.7±2.6 0.036
Sleep and fatigue
Fatigue VAS (change in score from baseline) −13.7±1.9 −23.0±1.9 <0.001 −26.2±1.9 <0.001
JSS (change in score from baseline), median (range)† −1.0 (−20, 7) −4.0 (−18, 8) <0.001 −5.0 (−20, 5) <0.001
FOSQ (change in score from baseline) 1.0±0.3 2.1±0.3 0.003 2.1±0.3 0.004
Functionality and HRQOL
  FIQ (total score)
      n (%) of total FIQ responders
      ≥14% criteria 79 (43.6) 119 (62.6) <0.001 131 (70.8) <0.001
      ≥30% criteria 54 (29.8) 95 (50.0) <0.001 102 (55.1) <0.001
      Total FIQ (change in score from baseline) −9.9±1.5 −19.2±1.5 <0.001 −20.6±1.5 <0.001
 SF-36
      PCS (change in score from baseline) 3.6±0.7 6.4±0.7 0.002 6.3±0.7 0.003
  EQ-5D overall health state
      EQ-5D (change in score from baseline) 5.1±2.2 9.2±2.2 NS 10.6±2.2 NS
Global impression of change
PGIC responders‡ n (%)  29 (16.0) 61 (32.1) <0.001 71 (39.7) <0.001
CGIC responders§ n (%) 34 (18.7) 68 (35.4) <0.001 69 (37.5) <0.001
Composites
Fibromyalgia composite responders¶ n (%) 21 (13.7) 42 (26.6) 0.005 53 (34.0) <0.001
Functional composite responders** n (%) 15 (9.8) 34 (21.7) 0.004 40 (26.0) <0.001
*Except when indicated otherwise, values are the least squares mean±SEM.
†Median values are presented due to skewed distribution of data.
‡Proportion of subjects who responded ‘very much better’ or ‘much better’.
§Proportion of subjects whose disease was rated ‘very much improved’ or ‘much improved’ by the investigator.
¶Includes pain VAS (≥30% reduction), FIQ total score (≥30% reduction) and PGIC responders (‘very much better’ or ‘much better’).
**Includes pain VAS (≥30% reduction), PGIC (‘very much better’ or ‘much better’) and SF-36 PCS (≥6 increase) responders.
CGIC, clinical global impression of change; EQ-5D, EuroQol-5 dimensions self-report questionnaire; FIQ, ﬁ  bromyalgia impact questionnaire; FOSQ, functional outcomes of sleep 
questionnaire; HRQOL, health-related quality of life; JSS, Jenkins sleep scale; MTPS, manual tender point survey; NS, not statistically signiﬁ  cant; PCS, physical component summary; 
PGIC, patient global impression of change; SEM, standard error of least squares mean; SF-36, Medical Outcomes Study 36-item short-form health survey; TPC, tender-point count; 
TPI, tender-point index; VAS, visual analogue scale.
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beyond pain reduction and encompass a broad range of symp-
toms. The onset of pain reduction occurred relatively rapidly 
and was maintained during the 14-week trial in most patients. 
Tenderness, reﬂ  ecting hyperalgesia and allodynia, a core domain 
to be assessed in all ﬁ  bromyalgia clinical trials,10 was decreased, 
as seen by a statistically signiﬁ  cant reduction in MTPS.
Improvement was not limited to pain, as multiple symptoms 
and general health, measured by the FIQ total score and SF-36, 
were also improved. A reduction of 14% or greater in FIQ, 
achieved by 62.6–70.8% of the SXB groups, is consistent with 
the MCID deﬁ  nition,33 whereas the reduction of 30% or greater 
in FIQ achieved by 50.0–55.1% of the SXB groups can be con-
sidered a moderate/good response. Moreover, the ﬁ  bromyalgia 
syndrome composite score, which is a more stringent measure 
that includes pain, FIQ and PGIC, was signiﬁ  cantly improved 
for both SXB 4.5 g/night and SXB 6 g/night versus placebo. In 
addition, a signiﬁ  cant improvement in the functional composite 
score following both SXB doses versus placebo was observed, 
even when it was based on a more stringent cut-off value for 
the SF-36 (≥6; as established for ﬁ  bromyalgia patients)30 than 
the MCID (3–5).34
The estimated NNT for 50% or greater pain reduction for 
SXB 4.5 g/night and SXB 6 g/night, 8 and 5, respectively, com-
pare favourably with an NNT of 6.4 for duloxetine (combined 
60 and 120 mg doses) for a similar treatment period (12–13 
weeks)35 and are superior to the NNT of 16 for pregabalin 450 
mg (the maximum recommended dose) for a 12-week treat-
ment period.36 This study is also the ﬁ  rst to evaluate NNT for 
the improvement of multidimensional function (FIQ) and shows 
that four to six patients need to be treated to achieve clinically 
relevant improvements.
Several study limitations should be noted. There was a high 
rate of discontinuation; however, discontinuations in the cur-
rent study were consistent with the 33–42% discontinuation 
rate in other ﬁ  bromyalgia phase 3 clinical trials.19 30 37–42 Another 
limitation, common to all clinical trials, is that the evaluated 
Tolerability and safety
The overall incidence of AE was comparable for SXB 4.5 g/night 
and SXB 6 g/night and higher than for placebo (table 4). Most 
AE were mild or moderate in severity. Treatment-emergent AE 
resulted in study discontinuation in 14.9% of SXB 4.5 g/night 
subjects and 20.6% of SXB 6 g/night subjects versus 5.3% for 
placebo.
The most frequently reported AE (≥5% and twice the rate for 
placebo) were nausea, dizziness, vomiting, insomnia, anxiety, 
somnolence, fatigue, muscle spasms and peripheral oedema. 
Eight subjects experienced treatment-emergent serious AE 
(three in the placebo, two in the SXB 4.5 g/night and three in 
the SXB 6 g/night groups); of these, two were considered to be 
related to study treatment (vomiting in one SXB 4.5 g/night sub-
ject and headache in one SXB 6 g/night subject). Weight loss 
was observed in the SXB-treated groups, with a mean (standard 
error) weight change from baseline of −1.19 (0.22) kg in the SXB 
6 g/night group and −0.43 (0.20) kg in the SXB 4.5 g/night group 
compared with a mean weight gain of 0.43 (0.16) kg in the pla-
cebo group. There were no deaths. More subjects in the SXB 
groups discontinued the study due to an AE compared with pla-
cebo (14.9% for SXB 4.5 g/night, 20.6% for SXB 6 g/night and 
5.3% for placebo); the most frequent AE leading to discontinu-
ation (≥3% and twice that for placebo) were nausea, headache, 
vomiting and anxiety (table 4).
DISCUSSION
This is the ﬁ  rst international study that evaluated the efﬁ  cacy 
and safety of SXB in a large number of ﬁ  bromyalgia patients. 
The rationale for using SXB was based on its ability to improve 
restorative sleep and the observation that disturbed sleep can 
cause hyperalgesia in chronic pain conditions by dysregulation 
of the descending pain inhibitory pathways.31 It was hypoth-
esised that the attainment of restorative sleep in SXB-treated 
patients should lead to a reduction in ﬁ  bromyalgia-related pain 
and other symptoms by restoring a more normal balance in these 
pathways, which are known to be dysfunctional in ﬁ  bromyal-
gia.32 The improvement in sleep quality as reﬂ  ected by changes 
in JSS (a validated measure for sleep quality in the ﬁ  bromyalgia 
population)24 and the improvement in ‘tired upon awakening’, 
one of the items in the FIQ that assesses sleep disturbance, sug-
gest that SXB may improve restorative sleep in ﬁ  bromyalgia 
patients. In addition, SXB treatment resulted in a statistically 
signiﬁ  cant reduction in pain and fatigue with both SXB dose 
groups compared with placebo. Reductions in pain were demon-
strated at 30% or greater and at 50% or greater and, in the SXB 
6 g/night group, at 80% or greater pain reduction. Particularly 
for those patients experiencing higher levels of pain reduction, 
these ﬁ  ndings represent clinically important changes that extend 
Table 3  NNT for improvement in pain and multidimensional function 
estimated in a post-hoc analysis
NNT (95% CI)
  SXB4.5g SXB6g
Pain VAS
  ≥30% 7 (5 to 18) 5 (3 to 7)
  ≥50% 8 (5 to 23) 5 (4 to 8)
  ≥80% 19 (10 to ∞) 11 (7 to 29)
FIQ improvement
  ≥14% 6 (4 to 12) 4 (3 to 6)
  ≥30% 5 (4 to 10) 4 (3 to 7)
FIQ, ﬁ  bromyalgia impact questionnaire; NNT, number needed to treat; SXB4.5g, sodium 
oxybate 4.5 g/night; SXB6g, sodium oxybate 6 g/night; VAS, visual analogue scale.
Table 4  Most frequent treatment-emergent AE and AE leading to 
discontinuation
Number (%) of subjects 
with AE
Placebo 
(n=188)
SXB4.5g 
(n=194)
SXB6g 
(n=189)
Total 
(N=571)
Most frequent 
AE (≥5% and twice 
the placebo rate)
Any AE 126 (67.0) 146 (75.3) 156 (82.5) 428 (75.0)
Nausea 16 (8.5)   37 (19.1)   40 (21.2)   93 (16.3)
Dizziness 3 (1.6)   23 (11.9)   25 (13.2)   51 (8.9)
Vomiting 6 (3.2)   10 (5.2)   16 (8.5)   32 (5.6)
Insomnia 6  (3.2)  15  (7.7)   8  (4.2)  29  (5.1)
Anxiety 3 (1.6)   10 (5.2)   15 (7.9)   28 (4.9)
Somnolence 3  (1.6)   7  (3.6)  11  (5.8)  21  (3.7)
Fatigue 4  (2.1)   6  (3.1)  11  (5.8)  21(3.7)
Muscle spasms 2 (1.1)     8 (4.1)   10 (5.3)   20 (3.5)
Oedema peripheral 4 (2.1)     3 (1.5)   12 (6.3)   19 (3.3)
Most frequent AE leading 
to discontinuation 
(≥3% and twice the 
placebo rate)
Any AE leading to 
discontinuation
10 (5.3)   29 (14.9)   39 (20.6)   78 (13.7)
Nausea 1  (0.5)   6  (3.1)  10  (5.3)  17  (3.0)
Headache 0   4  (2.1)   8  (4.2)  12  (2.1)
Vomiting 1  (0.5)   3  (1.5)   6  (3.2)  10  (1.8)
Anxiety 1 (0.5)   1  (0.5)   6  (3.2)   8  (1.4)
AE, adverse event; SXB4.5g, sodium oxybate 4.5 g/night; SXB6g, sodium 
oxybate 6 g/night.
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population may not necessarily be representative of clinical 
practice. Demographically, the characteristics of patients in the 
current study were what may be expected clinically43 44 and 
were comparable to study populations in clinical trials for the 
approved ﬁ  bromyalgia agents (predominantly female, middle 
aged, Caucasian, overweight and with ﬁ  bromyalgia symptoms 
for approximately 10 years).30 35–40
The results from this study, demonstrating the association of 
sleep quality restoration with the multidimensional improve-
ments in ﬁ  bromyalgia symptoms, are consistent with the long-
held notion that non-restorative sleep may play a role in the 
pathophysiology of ﬁ  bromyalgia12 and reinforce the recommen-
dation that the restoration of sleep quality should be a therapeu-
tic aim in ﬁ  bromyalgia.10 However, this is a challenging goal as 
many current treatments, such as hypnotics and antidepressants, 
improve insomnia but may have limited effect on sleep quality 
and, in particular, non-refreshed sleep.45 It is possible that SXB 
may improve ﬁ  bromyalgia symptoms by other as yet uniden-
tiﬁ  ed mechanisms, aside from an improvement in sleep qual-
ity. Further analysis and mechanistic studies will be required to 
explore these possibilities.
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